Welcome to our dedicated page for Journey Medical news (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical stock.
Journey Medical Corporation develops, sells and markets FDA-approved prescription pharmaceutical products for dermatological conditions. The company is a commercial-stage dermatology pharmaceutical issuer with a portfolio of branded prescription drugs marketed in the United States.
Recurring news for DERM centers on quarterly and annual financial results, corporate updates, and commercialization progress across its dermatology portfolio. Company updates frequently discuss Emrosi™, a modified-release minocycline product approved for inflammatory lesions of rosacea in adults, including payer access, group purchasing organization contracts, prescription demand, product revenue, and clinical data presentations or publications for Emrosi/DFD-29.
Journey Medical , a pharmaceutical company specializing in dermatological products, will announce its first quarter 2024 financial results on May 13, 2024. The company will host a conference call to discuss the results and provide a corporate update at 4:30 p.m. ET on the same day.
Journey Medical has appointed Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Benesch brings over 25 years of experience in financial leadership and reporting, with a focus on the pharmaceutical industry. The company's Co-Founder, President, and CEO praised Benesch's expertise and contributions to the finance and accounting team, emphasizing his role in upcoming milestones like the potential approval of DFD-29 for rosacea treatment. Benesch's extensive background includes positions at Teligent Pharma Inc., Torrent Pharmaceuticals, Savient Pharmaceuticals, Adare Pharmaceuticals, and Edenbridge Pharmaceuticals, along with experience at Baker Tilly Virchow Krause, LLP, and Ernst and Young. With a BA in accounting and CPA certification from Wilkes University, Benesch aims to drive sustainable value for Journey Medical and its shareholders while supporting patients with dermatological products.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.